Foresite Capital Management VI LLC Makes New Investment in Natera, Inc. $NTRA

Foresite Capital Management VI LLC bought a new stake in shares of Natera, Inc. (NASDAQ:NTRA) in the fourth quarter, Holdings Channel reports. The fund bought 67,356 shares of the medical research company’s stock, valued at approximately $15,431,000. Natera accounts for approximately 4.7% of Foresite Capital Management VI LLC’s investment portfolio, making the stock its 7th largest holding.

Several other large investors have also recently made changes to their positions in NTRA. Foresite Capital Management V LLC bought a new stake in shares of Natera in the 4th quarter worth approximately $15,431,000. OMERS ADMINISTRATION Corp bought a new position in Natera during the 4th quarter valued at approximately $1,989,000. Silvant Capital Management LLC increased its position in Natera by 0.8% during the 4th quarter. Silvant Capital Management LLC now owns 15,524 shares of the medical research company’s stock valued at $3,556,000 after buying an additional 122 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its stake in Natera by 1.3% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 13,252 shares of the medical research company’s stock valued at $3,036,000 after buying an additional 166 shares during the last quarter. Finally, Panagora Asset Management Inc. raised its stake in Natera by 42.3% during the fourth quarter. Panagora Asset Management Inc. now owns 393,420 shares of the medical research company’s stock valued at $90,129,000 after buying an additional 116,951 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on NTRA. Piper Sandler reissued an “overweight” rating and issued a $249.00 target price on shares of Natera in a research note on Tuesday, May 12th. Wells Fargo & Company upped their price target on shares of Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. The Goldman Sachs Group initiated coverage on shares of Natera in a research report on Friday, June 5th. They set a “neutral” rating and a $245.00 price objective on the stock. Evercore restated an “outperform” rating and set a $270.00 price objective on shares of Natera in a research note on Friday, May 8th. Finally, William Blair assumed coverage on shares of Natera in a research note on Tuesday, April 14th. They issued an “outperform” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $256.53.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $216.97 on Tuesday. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $256.36. The company has a market cap of $31.07 billion, a P/E ratio of -133.11 and a beta of 1.56. The stock’s fifty day moving average price is $206.67 and its 200-day moving average price is $215.69.

Insider Buying and Selling

In other news, insider John Fesko sold 1,438 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $202.84, for a total transaction of $291,683.92. Following the transaction, the insider directly owned 185,782 shares of the company’s stock, valued at $37,684,020.88. This represents a 0.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Gail Boxer Marcus sold 11,000 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $217.21, for a total value of $2,389,310.00. Following the completion of the transaction, the director owned 6,183 shares in the company, valued at approximately $1,343,009.43. This trade represents a 64.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 159,378 shares of company stock valued at $34,640,860 in the last ninety days. Corporate insiders own 5.05% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.